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We  describe  here  the  synthesis,  characterization,  bioconjugation,  and  application  of water-soluble
thioglycolic  acid  TGA-capped  CdTe/CdS  quantum  dots  (TGA-QDs)  for targeted  cellular  imaging.  Anti-
human  epidermal  growth  factor  receptor  2 (HER2)  antibodies  were  conjugated  to  TGA-QDs  to target
HER2-overexpressing  cancer  cells.  TGA-QDs  and  TGA-QDs/anti-HER2  bioconjugates  were  character-
ized  by  ﬂuorescence  and  UV–Vis  spectroscopy,  X-ray  diffraction  (XRD),  hydrodynamic  sizing,  electron
microscopy,  and  gel  electrophoresis.  TGA-QDs  and  TGA-QDs/anti-HER2  were  incubated  with  cells  toeywords:
uantum dots
nti-HER2
ioconjugation
ell speciﬁc targeting
maging
examine  cytotoxicity,  targeting  efﬁciency,  and  cellular  localization.  The  cytotoxicity  of particles  was  mea-
sured  using  an  MTT  assay  and  the no  observable  adverse  effect  concentration  (NOAEC),  50%  inhibitory
concentration  (IC50), and  total  lethal  concentration  (TLC)  were  calculated.  To evaluate  localization  and
targeting  efﬁciency  of  TGA-QDs  with  or without  antibodies,  ﬂuorescence  microscopy  and  ﬂow  cytome-
try  were  performed.  Our  results  indicate  that  antibody-conjugated  TGA-QDs  are well-suited  for  targeted
cellular imaging  studies.. Introduction
Cancer is one of the leading causes of death worldwide. Early
etection of tumor cells can prevent approximately 3.0% to 35% of
ancer deaths; thus, it is essential that imaging probes be developed
or the early diagnosis of cancer [1,2]. Functionalized ﬂuores-
ent nanoparticles, such as quantum dots (QDs), are promising
robes for biomedicine and cancer research [3,4]. As ﬂuorescent
robes, QDs are fundamentally different from organic dyes [5].
lthough successful cell labeling has been achieved with organic
yes, they are plagued by low quantum yields and photobleach-
ng. QDs overcome many these problems due to their excellent
hysical and ﬂuorescent properties [6], including broad absorption
pectra, narrow emission spectra [7,8], high quantum yields, resis-
ance to photobleaching, and high photochemical stability [9,10].
 This is an open-access article distributed under the terms of the Creative Com-
ons Attribution-NonCommercial-No Derivative Works License, which permits
on-commercial use, distribution, and reproduction in any medium, provided the
riginal author and source are credited.
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Therefore, biocompatible QDs are ideal for cell-labeling studies
[11].
Because of the large surface area of QDs, they are readily mod-
iﬁed with surface-conjugated biomolecules and proteins [12–14].
QDs are commonly used to image tumor cells after surface label-
ing with peptides, antibodies, or receptor ligands, such as folate
[15]. Guan et al. characterized transferrin-conjugated CdTe/CdSe
QDs by different methods and evaluated their cellular target-
ing capabilities [16]. In another study, RNase-A-associated CdTe
QD clusters were coupled to monoclonal antibodies against the
human epidermal growth factor receptor 2 (HER2). These ther-
anostic QDs were then used to image and treat gastric cancer
in situ in a mouse model [17]. Yu et al. reported using GSH-TGA-
QDs-ND-1 probes that speciﬁcally react with the LEA antigen to
target colorectal cancer cells [18]. Geszke-Moritz et al. evaluated
the accumulation of folate-conjugated, thioglycerol-capped, Mn-
doped ZnS QDs and their subsequent cytotoxicity in T47D breast
cancer cells [19]. Recently, Liu et al. synthesized water-soluble
indium phosphide/ZnS QDs (QInP) that were functionalized with
carboxyl groups and polyethylene glycol (PEG). QinP were then
loaded into cells with cell-penetrating peptides (CPP) [20].
Biomedical applications require water-soluble QDs [21]. How-
ever, QDs are typically produced in organic solvents, making them
reserved.
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nsuitable for direct use in biological studies [22]. For cell imaging,
he QDs must be transferred into aqueous solutions using ligand
xchange reactions, and then conjugated to relevant biomolecules
efore being incubated with cells [23,24]. Pretreatments, such as
igand exchange, increase the size of QDs, which can make them
mpracticable for in vitro applications [25]. By modiﬁcation with
ydrophilic surface moieties that interact with the aqueous phase,
Ds can be rendered water soluble without any additional modiﬁ-
ation [26].
Antibodies are commonly used targeting moieties because of
heir diversity and high speciﬁcity [27]. For cell imaging, QDs have
een modiﬁed with cell-targeting antibodies against various anti-
ens, such as the epidermal growth factor receptor (EGFR) [26],
h-interferon [28], and HER2 [29]. Lung cancer cells often overex-
ress the erbB (HER) family of oncogenes [30,31]. The c-erbB2 gene
ncoding the HER2 protein is expressed in 20–30% of non-small cell
ung cancers (NSCLCs) and, especially, adenocarcinoma [31,32].
The objective of the study was to design and synthesize
uorescent probes for cell-targeting studies. Water-soluble,
hioglycolic acid (TGA)-capped QDs (TGA-QDs) were labeled
ith anti-HER2 antibodies to speciﬁcally image HER2-
ositive A549 lung cancer cells. Due to the carboxyl groups
resent on TGA-capped QDs, a simple reaction using 1-
thyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and
-hydroxysuccinimide (NHS) conjugated antibodies to QDs.
xpression of the HER2 receptor in A549 cells and NIH-3T3 control
ells was conﬁrmed by PCR and ﬂow cytometry. Targeting speci-
city of the TGA-QD/anti-HER2 conjugates was characterized by
everal methods. Finally, the cellular internalization of QDs was
isualized by ﬂuorescence microscopy.
. Materials and methods
.1. Materials
All chemicals used here were of the highest purity avail-
ble. Cadmium chloride (CdCl2, 99%) was ordered from Fluka.
hioglycolic acid (TGA, HSCH2CO2H, 98%) was purchased from
erck. Tellurium precursor (NaHTe) was prepared from the
eaction between sodium borohydride (NaBH4, Riedel 95%)
nd tellurium powder (Te, Fluka 99.9%). Thiourea (CH4N2S,
ldrich 99.5%) was the sulfur source for CdS shell forma-
ion. 2-Propanol (C3H8O, Riedel 99.5%) was used to purify
he nanoparticles. All precursor solutions were prepared using
ltra-pure water as a solvent. Rabbit monoclonal antibody
gainst human HER2 protein was obtained from Diagnostic
iosystems. 2-(N-morpholino) ethanesulfonic acid (MES), 1-ethyl-
-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC),
-hydroxysuccinimide (NHS), 3-(4,5-dimethylthiazol-2-yl)-2,5-
iphenyl tetrazoliumbromide (MTT), 4,6-diamino-2-phenylindol
DAPI) and Dulbecco’s Modiﬁed Eagle Medium (DMEM) were
rdered from Sigma Aldrich. Sodium dodecyl sulfate (SDS) and
NAtidy G were purchased from Applichem. Phosphate-buffered
aline (PBS) was prepared with 137 mM sodium chloride, 2.7 mM
otassium chloride, 10.1 mM disodium hydrogen phosphate and
.8 mM potassium dihydrogen phosphate, pH 7.4; all chemicals
ere provided from Sigma Aldrich. The chemicals for protein
xpression analysis, chloroform, ethanol (75%) and the ingredi-
nts of Tris-acetate-EDTA buffer (TAE) that consists of 40 mM
-Amino-2-(hydroxymethyl)-1,3-propanediol (tris-base), 20 mM
lacial acetic acid and 1.0 mM ethylenediaminetetraacetic acid
EDTA), pH 8.0 were purchased from Sigma Aldrich. Oligo(dT)12–18
rimer, agarose and Roti-Safe GelStain were ordered from Carl
oth GmbH (Karlsruhe, Germany). The dNTP Set (100 mM solu-
ions) and GeneRuler 100 bp DNA Ladder were obtained fromiointerfaces 114 (2014) 96– 103 97
Fermentas. M-MLV  reverse transcriptase and its M-MLV RT 5×
buffer as well as GoTaq polymerase and its 5× Green GoTaq reaction
buffer were provided from Promega (Mannheim, Germany). PCR
primers were synthesized by life technologies. Chemicals for native
PAGE experiment, ammoniumpersulfate (APS), tetramethylenedi-
amine (TEMED), tris–hydrochloric acid, glycine and bromophenol
blue were obtained from Sigma Aldrich. Forty percent acry-
lamide/bisacrylamide mixing ratio, 37.5:1 was purchased from Carl
Roth GmbH. Glycerol was  ordered from Fluka.
2.2. Synthesis of water soluble TGA-QDs
In a typical synthesis of CdTe QDs a modiﬁed one pot method
from the literature was  used [33]. Both Te2− and Cd2+ precur-
sors were prepared separately. Sodium hydrogen telluride (NaHTe)
was prepared by reduction of Te powder with sodium borohydride
(NaBH4). Te powder (0.0918 g) and NaBH4 (0.06 g) were put into
25 mL  reaction ﬂask and it was purged with N2 for 30 min. Then
10 mL  of deaerated distilled water was  added to the reaction ﬂask
and the system was  heated to 60 ◦C for 2 h under N2 atmosphere to
obtain a solution with a purple color.
3.12 mmols of CdCl2 and 420 L of thioglycolic acid were dis-
solved in 110 mL  of ultra-pure water in a two-necked ﬂask with a
septum. pH of the solution was  adjusted to 11.0–11.5 by drop wise
addition of NaOH solution (1.0 M).  Then the ﬂask was attached to
the condenser under N2 for an hour at 80 ◦C to purge oxygen in the
medium. The reﬂux time was one hour. Further reﬂux before the
addition of Te2− precursor may  cause decomposition of thioglycolic
acid to give S2− [34]. Then 2.5 mL  freshly synthesized NaHTe (Te2−
precursor) was  added to the solution and the reaction temperature
was increased to 110 ◦C.
Formation and growth steps are proceeding upon reﬂux. As
soon as the temperature reaches to 110 ◦C, sampling was started
to observe the growth of the particles. After 10 min, the solution
emitted green light under UV-irradiation.
To increase the photostability of the nanoparticles, CdTe NCs
were coated with CdS shell. CdS is preferred as a shell material for
CdTe cores because band gap of CdS (2.5 eV) is wider than that of
CdTe (1.5 eV) and also lattice parameter mismatch between CdTe
and CdS is about 3.6% [35].
Proper amount of thiourea dissolved in ultra-pure water was
added to green emitting CdTe QDs. The ratio of Te:S related to
the amount of applied Te was  optimized to 1:10. After addition
of thiourea solution, reﬂux was  continued. The prolonged reﬂux
results in red-shifting in both UV–Vis and ﬂuorescence spectra
upon coating are indication of core/shell structure formation rather
than CdTexS1−x alloyed structure. CdTeS alloy structure has larger
band gap energy than CdTe and the alloy formation will cause blue-
shifting rather than red-shifting. By a changing reﬂux time, proper
sized QDs can be prepared.
2.3. Characterization of TGA-QDs
The synthesized QDs were characterized both optically and
structurally. UV–Vis Spectrometer and ﬂuorescence spectro-
photometer were used for characterization of optical properties
of the nanocrystals. Fluorescence and absorbance spectra of QDs
were measured with Varian Cary Eclipse ﬂuorescence spectropho-
tometer and Varian Cary 50 UV–Vis absorption spectrophotometer.
Quantum yield of emission from the QDs is deﬁned as ratio of
number of emitted photons to absorbed photons by the QDs. Exper-
imentally the quantum yield can be calculated by absorption and
ﬂuorescence emission spectra by comparing ﬂuorescence of both
unknown substance and a dye of known quantum yield [36]. Quan-
tum yield of emission from the QD’s were measured by using
Rhodamine 6G in water as a standard (the reference quantum
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ield of 0.95).Structural characterization of the nanoparticles was
one by X-Ray Diffractometry (XRD), and transmission electron
icroscopy (TEM). X-ray powder diffraction patterns of the QDs
ere obtained by using a Philips X’pert Pro X-ray diffractometer.
he grounded samples were placed on a zero-background silicon
ample holder. Data was collected by using CuK ( = 1.5406 A˚)
adiation at settings of −45 kV and 40 mA  for 45 min. The scan rate
as 0.1/sn and the data was collected for 2 values of 5.0 to 60. TEM
mages were taken by using JEOL microscope. For the analyses, a
rop of QD solution was placed onto a copper grid surface and dried
t room temperature. The samples were placed onto the holder then
iven to the microscope and images were acquired using a voltage
f 200 kV.
.4. Preparation of TGA-QDs bioconjugate
TGA-QDs/anti-HER2 conjugates were prepared as follows: 2.0 M
DC and 0.5 M NHS were separately prepared in 25 mM (pH 6.0)
ES  buffer. A volume of 200 L QDs solutions (0.91 mg/mL) were
ixed with 25 L EDC and 25 L NHS at room temperature to acti-
ate carboxyl groups of TGA-QDs. Then, anti-HER2 antibody was
dded and reaction was completed in 4 h at room temperature.
inally, the bioconjugates were puriﬁed using 300 kDa membrane
lter (Sartorius Stedim Biotech) and washed with PBS three times.
.5. Characterization of TGA-QDs bioconjugate
To verify the successful preparation of bioconjugates both a
ative PAGE and agarose gel were used. Samples of conjugates
nd pure quantum dots were separated in 2.0% agarose gel in
AE buffer at 98 V for 15 min  by Thermo EC electrophoresis unit.
herefore 30 L of samples were mixed with 10 L two-fold load-
ng dye, consisting of 23.9 M formamide, 0.867 mM SDS, 0.373 mM
romophenol blue, 0.464 mM xylenecyanol, 0.5 mM EDTA. For
he native PAGE, 15% running gel was prepared using 1875 L
0% acrylamide/bisacrylamide (37.5:1), 500 L bidistilled water,
400 L Tris–HCl (1.5 M,  pH 8.8), 1225 L bidistilled water, 10 L
EMED and 10 L APS. 6.0% stacking gel was prepared using
50 L 40% acrylamide/bisacrylamide (37.5:1), 300 L bidistilled
ater, 630 L Tris–HCl (0.5 M,  pH 6.8), 3770 L bidistilled water,
0 L TEMED and 10 L APS. For preparation of running buffer
.63 g Tris and 15.96 g glycine were added in 600 mL  water and
djust to pH 8.9. Samples of conjugates and pure anti-HER2
ntibody were added in 20 L sample buffer including 5.0 mL  glyc-
rol, 2.7 mL  water, 2.13 mL  Tris–HCl (0.5 M,  pH 6.8) and a trace
mount bromophenol blue. Gel was run by using mini Protean
II electrophoresis unit (Bio-Rad) at 30 mA/100 V. Finally, the gel
as stained with silver. For the characterization of sizes, sam-
les were diluted 1:10 with PBS (pH 7.4) and the hydrodynamic
iameters of QDs and TGA-QDs/anti-HER2 conjugates were eval-
ated by using dynamic light scattering (DLS, Malvern Zetasizer
anoseries-Nano-ZS). Fluorescence spectra of TGA-QDs/anti-HER2
onjugates were measured with Varian Cary Eclipse ﬂuorescence
pectrophotometer and by using 2.0 L of sample for Nanodrop
300 spectroﬂuorometer (Thermo Fisher Scientiﬁc Inc. USA) in
erms of relative ﬂuorescence units (RFU). The effect of conjugation
n the ﬂuorescence characteristics of QDs was examined according
o the ﬂuorescence spectrum. Photostability of TGA-QDs/anti-HER2
as tested via measuring ﬂuorescence intensity of conjugates for
0 days, stored at 4 ◦C in the dark.
The Bradford protein assay was used for the analysis of proteinontent in the bioconjugate using Coomassie Brilliant Blue G-250
y following of the optical densities at 595 nm.  The protein con-
entration of the sample is determined by comparison to that of
 series of BSA standards. The amount of bound anti-HER2 in theiointerfaces 114 (2014) 96– 103
QD bioconjugate was  then calculated. A microplate reader (Thermo
Labsystems Multiscan Spectrum) was  used for the analysis.
2.6. Cell line
A549 (human lung cancer) and NIH-3T3 (mouse ﬁbroblast)
cell lines were provided from German Collection of Microorgan-
isms and Cell Cultures (DSMZ). Cell culture supplies including
fetal calf serum (FCS Gold), Newborn Calf Serum (NCS) and
penicillin/streptomycin (P/S, 100×) were purchased from PAA Lab-
oratories GmbH. A549 cells were grown in DMEM containing 10%
FCS and 1.0% P/S. NIH-3T3 cells were cultivated in DMEM con-
taining 10% NCS and 1.0% P/S. All cells were cultivated in medium
and incubated with samples and reagents at 37 ◦C in humidiﬁed
environment with 5.0% CO2.
2.7. HER2 expression on cell surfaces
Expression of the HER2 receptor in A549 and lack of expres-
sion in NIH-3T3 cells as control cell line was ﬁrst conﬁrmed by
PCR and ﬂow cytometry analysis. Therefore, total cellular RNA
of 2 × 106 cells was isolated, transcribed into cDNA and used for
PCR following the same procedures as described in our earlier
publication [37]. The PCR primer pair for the c-erbB2 gene was
designed with Lasergene PrimerSelect Software using the NCBI
reference mRNA sequence for homosapiens v-erbB2 erythrob-
lastic leukemia viral oncogene homolog 2 (homo sapiens erbB2,
NM 001005862.1). The primer sequences are as followed: erbB2
human forward 5′tgc ggc tcg tac aca ggg act t3′, reverse 5′tgc ggg aga
att cag aca cca act3′. To verify the success of reverse transcription a
primer pair for the human housekeeping gene hypoxanthine phos-
phoribosyltransferase (HPRT) and the mouse housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were addi-
tionally used. The primer sequences are: HPRT forward 5′-aag ctt
gct ggt gaa aag ga-3′ and reverse 5′-aag cag atg gcc aca gaa ct-
3′, as well as GAPDH forward 5′-aac ttt ggc att gtg gaa gg-3′ and
reverse 5′-aca cat tgg ggg tag gaa ca-3′. The polymerase chain reac-
tions was  performed using the protocol described in our earlier
publication24, but for erbB2 expression analysis 2.0 L cDNA and
31.75 L distilled autoclaved water were used. For expression anal-
ysis of c-erbB2 an annealing temperature of 64 ◦C, for HPRT of 60 ◦C
and for GAPDH of 58 ◦C were used. Products of PCR were sepa-
rated in 1.5% agarose gel in TAE buffer stained with 5.0 L/100 mL
buffer Roti-Safe GelStain ready-to-use by Thermo EC electrophore-
sis unit at 100 V for 60 min. The gel was  documented using an INTAS
UV documentation system. For ﬂow cytometry studies, the same
procedure as previously described [37] was used. For staining of
5×105 cells 0.04 g mouse IgG1 anti-human HER2-FITC antibody,
clone Neu 24.7 (BD Biosciences, Heidelberg) were added and cell
suspension was shaken at room temperature for 1 h with 500 rpm
in the dark. As negative control cells were stained using mouse
IgG1, k FITC isotype control antibody (BD Biosciences, Heidelberg).
The stained cells were analyzed in a COULTER EPICS XL-MCL ﬂow
cytometer. At least 10 000 gated events were observed in total and
living cells were gated in a dot plot of forward versus side scatter
signals. For drawing dot plots and histograms the software WinMDI
2.9 was  used.
2.8. Cytotoxicity
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT) assays were used to determine dose dependent
cytotoxicity of TGA-QDs and bioconjugates. Cells were seeded out
in 96-well-tissue plates (Sarstedt, USA) in a volume of 200 L.
The cultivation took three days at 37 ◦C, 5.0% CO2 and 100% air
humidity. After this cultivation time the wells were grown until
reaching conﬂuence. A549 and NIH-3T3 cells were washed once in
s B: Biointerfaces 114 (2014) 96– 103 99
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Fig. 1. (A) XRD pattern of CdTe/CdS QDs. Blue lines show 2 theta of face centered
cubic bulk CdTe (bottom), red lines represent the 2 theta of face centered cubic
bulk CdS (top), (B) TEM images of CdTe/CdS core shell QDs, scale bar: 5.0 nm. (For
interpretation of the references to color in this ﬁgure legend, the reader is referredD. Ag et al. / Colloids and Surface
BS and treated with TGA-QDs and TGA-QDs/anti-HER2 conjugates
t 5, 10, 20, 30, 60, 120, 180 and 240 g/mL concentrations for
 h. Then the samples were removed completely and cells were
ncubated in 110 L/well 10% MTT  solution (5.0 mg/mL PBS) in
upplements-free medium for 4 h. With this incubation time the
ormazan complex was produced inside the cells. To release the
urple coloured salt, 100 L SDS solution (1.0 g SDS in 10 mL  0.01 M
Cl) were added per well and after 24 h of incubation, UV–Vis
bsorption was measured at 570 nm with 630 nm as reference
avelength using a microplate reader Model 680 (BioRad).
.9. Cellular uptake study by ﬂow cytometry
For ﬂow cytometry studies the cells were harvested by accu-
ase treatment, washed once in ice-cold PBS and incubation buffer
onsisting of PBS supplemented with 2.0% FCS. Then 3 × 105 cells
n incubation buffer were collected and centrifuged. For cell stain-
ng 40 g/mL TGA-QDs/anti-HER2 conjugates were added and cell
uspension was shaken at room temperature for 1 h with 450 rpm
n the dark. Cells were washed once in 500 L incubation buffer to
emove unbound conjugates. Before ﬂow cytometric analysis cells
ere suspended in 300 L incubation buffer and then analyzed in a
OULTER EPICS XL-MCL ﬂow cytometer. The analysis of measured
ignals was done as described above.
.10. Fluorescence microscopy
A549 and NIH-3T3 cells were cultivated for three days on glass
hamber slides (Nunc) in a volume of 200 L medium until 80%
onﬂuence was reached. TGA-QDs/anti-HER2 conjugates and TGA-
Ds were diluted with medium and 100 L of samples (60 g/mL)
ere added to the cells. The cells were incubated for 2 h at 37 ◦C
nd were washed twice in PBS. Afterwards cell’s nuclei were
ounterstained by DAPI solution (1.0 g/mL) for 15 min  and cells
ere washed again twice in PBS. Conjugate-labelled cells were
overed with ﬂuoroshield (Carl Roth) and imaged using Olym-
us BX53F ﬂuorescence microscope equipped with a CCD camera
Olympus DP72). For QDs ﬂuorescence a U-MNB excitation ﬁlter,
P470-490 (exciter ﬁlter), BA515 (barrier ﬁlter) and for DAPI ﬂu-
rescence a U-MWU  excitation ﬁlter, BP330-385 (exciter ﬁlter),
A420 (barrier ﬁlter) were used. To ﬁgure out if the internal-
zation process is driven by endocytotic pathways, cells were
tained as described before, but incubated at a temperature of
◦C.
. Results and discussion
.1. Characterization of QDs
QDs with CdTe cores and CdS shells exhibited a diffraction pat-
ern similar to that of bulk cubic CdTe. The crystal structure of
dTe/CdS QDs was a zincblende type. The XRD pattern of the QDs
esembled the general pattern of the cubic lattice. The diffraction
eaks shifted to larger angles, which were between those of cubic
dTe and CdS crystals. The peak locations between CdTe and CdS
rystals indicated formation of a CdS shell (Fig. 1A).
The mean particle size was 5.4 ± 1.8 nm according to dynamic
ight scattering (DLS) (Malvern Zetasizer). The diameter was  con-
rmed to be ∼5.0 nm by transmission electron microscopy (TEM)
Fig. 1B). The normalized absorbance and ﬂuorescence spectra of
Ds are shown in Fig. S1. Emission wavelengths of CdTe/CdS QDs
ere tuneable by adjusting the reaction times. Yellow-emitting
Ds were used (em = 560 nm)  during the experiments and the
uantum yield of emission from the QDs was ∼36% at an excitation
avelength of 488 nm.to  the web  version of this article.)
3.2. Characterization of TGA-QD bioconjugates
Different methods have been used to conjugate antibodies
to carboxy-functionalized QDs [23,38]. We  conjugated anti-HER2
antibodies to TGA-QDs using EDC/sulfo-NHS coupling reactions
that covalently linked antibodies to TGA-QDs. During this pro-
cess, NHS was  used as an activating agent for carboxyl groups on
the TGA-QDs. NHS formed amide linkages to amines on antibod-
ies. Gel electrophoresis in 2.0% agarose and polyacrylamide was
used to verify antibody conjugation qualitatively. The antibody-
conjugated QDs appeared to be heavier upon electrophoresis than
QDs, demonstrating conjugation (Fig. 2A). DLS, TEM, and Bradford
assays were performed to characterize the antibody-conjugated
QDs. The hydrodynamic diameter increased to 14.33 ± 2.0 nm
after bioconjugation (Fig. 2B). Protein content was determined
using Bradford assays, which compared experimental values to a
bovine serum albumin (BSA) standard curve (y = 1.2214x + 0.0028,
R2 = 0.9943). The starting amount of antibody was  3.925 g. After
conjugation, TGA-QDs were washed with PBS to remove unbound
antibodies, and the binding efﬁciency was determined to be
50%.
100 D. Ag et al. / Colloids and Surfaces B: B
Fig. 2. Conﬁrmation of conjugation of TGA-QDs with anti-HER2 (A) 2.0% agarose gel
(
o
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The cytotoxicity of Cd-based QDs is thought to occur from
2+
F
n
cB)  hydrodynamic diameters of TGA-QDs and TGA-QDs/anti-HER2.
The amount of antibody conjugated to TGA-QDs was  10.67 g
f protein per 1 mg  of QDs.
The potential effects of antibody conjugation on the ﬂuores-
ence characteristics of TGA-QDs were measured by ﬂuorescence
pectroscopy. Antibody conjugation reduced the ﬂuorescence
ntensity of TGA-QDs, but did not shift the emission wavelength.
verall, antibody conjugation did not dramatically affect the ﬂuo-
escent properties of TGA-QDs (Fig. S3).
ig. 3. (A) For c-erbB2 expression in A549 and NIH-3T3 cells. (B) A549 cell characterization
egative control, black: Cells stained with anti-human HER2-FITC. Measured relative ﬂuo
olor  in this ﬁgure legend, the reader is referred to the web  version of this article.)iointerfaces 114 (2014) 96– 103
3.3. Photostability
QDs must be photostable for cell-imaging experiments. Due to
their high photostability, similar QDs have been successfully used
for in vivo tumor targeting studies [39]. Byrne showed that QDs
are suitable for cell imaging studies because of their high photosta-
bility [40]. We measured the photostability of TGA-QDs/anti-HER2
conjugates stored in the dark at 4 ◦C and measured their ﬂuores-
cence intensity for 30 days. Stored under these conditions, QDs
remained ﬂuorescent for 30 days without any signiﬁcant decrease
in ﬂuorescence.
3.4. HER2 expression on cell surfaces
To test QDs as cellular imaging probes, we measured cellu-
lar HER2 expression using polymerase chain reaction (PCR) and
HER2 expression on cell surfaces using ﬂow cytometry. The PCR
results are shown in Fig. 3. The housekeeping gene hypoxanthine
phosphor-ribosyltransferase (HPRT) was  measured as a control
for A549 cells, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) served as the control for NIH-3T3 cells (Fig. S4). Bands
corresponding to housekeeping genes were observed for both cell
types (263 bp for A549 cells and 224 bp for NIH-3T3 cells). Fig. 3A
shows a HER2 band at 420 bp in A549 cells that is absent in NIH-3T3
cells.
The PCR results were also conﬁrmed at the protein level by
using ﬂuorescently labeled antibodies and ﬂow cytometry. The ﬂow
cytometry results using at least 10 000 cells per measurement are
shown in Fig. 3. Cells were incubated with a ﬂuorescein isothio-
cyanate (FITC)-labeled mouse IgG1 isotype as a negative control or
a FITC-labeled mouse HER2 antibody. Partial image S5 ﬁgures out
the ﬂuorescence measurement of NIH-3T3 cells and Fig. 3B shows
the signals of A549 cell line. The mean intensity of isotype controls
for NIH-3T3 cells was 2.7 AU, whereas the isotype control for A549
was 1.9 AU. The mean ﬂuorescence intensity after incubating with
the anti-HER2 antibody was 2.7 AU for NIH-3T3 cells, but 6.9 AU
for A549 cells. Both methods conﬁrmed that HER2 expression was
considerably higher in A549 cells than in NIH-3T3 cells.
3.5. Cytotoxicityreleased Cd ions [41]. Using QDs with shells or coatings minimizes
Cd2+ release from the particle surface [42]. Su et al. demonstrated
that uncoated CdTe QDs are toxic to cells, but coating the surface
 for HER2 protein expression via ﬂow cytometry, red: Cells incubated with IgG-FITC
rescence intensities are given as numbers. (For interpretation of the references to
D. Ag et al. / Colloids and Surfaces B: Biointerfaces 114 (2014) 96– 103 101
Fig. 4. (A) Dose dependent cytotoxic effects on viability of A549 (B) NIH-3T3 cells
(Black curve: Cells incubated with TGA-QDs, red curve: Cells incubated with TGA-
QDs/anti-HER2, black dot line represents point of signiﬁcant cytotoxicity (70%
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Niability). Values are the mean ± standard deviation of the data (N = 4). (For inter-
retation of the references to color in this ﬁgure legend, the reader is referred to the
eb  version of this article.)
ith a CdS layer reduces toxicity [43]. To evaluate the dose-
ependent cytotoxic effects of our QD preparations, the viability
f NIH-3T3 and A549 cells were determined using a standard MTT
ssay. NIH-3T3 and A549 cells were incubated with anti-HER2 TGA-
Ds or TGA-QDs alone for 2 h at different concentrations, and cell
iability was measured (Fig. 4). A cytotoxic effect was  observed
or both cell lines incubated with TGA-QDs/anti-HER2; however,
GA-QDs alone did not show signiﬁcant cytotoxicity. It is possi-
le that the increase in cytotoxicity was caused by interactions
etween the TGA-QDs/anti-HER2 and the cells, which is consistent
ith previous ﬁndings [44].
Cytotoxicity data obtained from MTT  assays were extrapo-
ated using the exponential equation (y = 1 − (1/(1 + ea × (b −
)))), where a is the slope, b is IC50 (50% inhibitory concentra-
ion) and x is the concentration of sample. Also, the no observable
dverse effect concentration (NOAEC) and total lethal concen-
ration (TLC) were calculated using similar equations. Estimated
oxicity values in terms of IC50, NOAEC, and TLC are shown in
able S1. The IC50 values of TGA-QDs/anti-HER2 conjugates is
pproximately were similar for A549 cells (IC50 = 105.4 g/mL) and
IH-3T3 cells (IC50 = 107.1 g/mL), but ∼6 times lower than the IC50Fig. 5. (A) Histogram of speciﬁc binding of TGA-QDs/anti-HER2 to HER2-negative
NIH-3T3 cells and HER2-positive A549 cells (B) concentration-dependent binding
of  TGA-QDs/anti-HER2 to A549 cells.
values for unconjugated TGA-QDs (IC50 = 696.7 g/mL for A549;
IC50 = 569.4 g/mL for NIH-3T3).
3.6. Cellular targeting and uptake
To conﬁrm the binding speciﬁcity of anti-HER2 TGA-QDs, they
were incubated with A549 and NIH-3T3 cells. After incubation
with anti-HER2 TGA-QDs, the ﬂuorescence intensity of A549 cells
was ∼2-fold greater than NIH-3T3 cells (Fig. 5A). These results
demonstrate that TGA-QDs/anti-HER2 conjugates bind to A549
cells in greater numbers than they do to NIH-3T3 cells. Caused by
a high ﬂuorescence intensity of the conjugated QDs, the measured
ﬂuorescence signal is increased, in comparison to the FITC ﬂuo-
rochrome used as staining dye for cell characterization (compare
Fig. 3). Fig. 5B shows the relationship between the concentra-
tion of TGA-QDs/anti-HER2 and labeling of A549 cells. Greater
concentrations of TGA-QDs/anti-HER2 resulted in greater ﬂuores-
cence intensities. Maximal ﬂuorescence values were measured at
TGA-QDs/anti-HER2 concentrations between 40 and 60 g/mL. For
further experiments, 60 g/mL TGA-QDs/anti-HER2 conjugate was
used.
Fluorescence microscopy of internalized TGA-QDs and TGA-
QDs/anti-HER2 was  performed after incubating QDs  with A549 cells
for 2 h at 37 ◦C or 4 ◦C (Fig. 6 and S6). Modifying the QD surface
with antibodies allows cellular uptake through endocytosis [45].
Fig. 6 and Fig. S6 show that TGA-QDs/anti-HER2 was endocytosed
into cells by receptor-mediated endocytosis. Incubating cells at 4 ◦C
blocks endocytosis [9]. Images of QDs incubated with A549 cells at
4 ◦C are shown in Fig. 6 and Fig. S7.
Nabiev et al. used TGA-capped CdTe QDs to study passive uptake
by cells [46]. They showed that negatively charged TGA-capped
CdTe QDs escape from endosomes and accumulate near nuclear
pore complexes. We  also observed that TGA-QDs accumulated in
and around the nucleus (Fig. 7A and Fig. S8). When the cells were
incubated with TGA-QDs at 4 ◦C, nanoparticles were not endocy-
tosed (Figs. 7B and Fig. S9).
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Fig. 6. Fluorescence microscopy imaging of A549 cells. Cells were treated with TGA-QDs/anti-HER2 bioconjugate for 2 h at 37 ◦C, (A) overlap of two images, control nuclei
staining with DAPI. Cells were treated with TGA-QDs/AntiHER2 bioconjugate for 2 h at 4 ◦C. (B) Overlap of two  images, control nuclei staining with DAPI.
Fig. 7. Fluorescence microscopy imaging of A549 cells. Cells were treated with TGA-QDs for 2 h at 37 ◦C, (A) overlap of two images, control nuclei staining with DAPI. Cells
were  treated with TGA-QDs for 2 h at 4 ◦C, (B) overlap of two  images, control nuclei staining with DAPI.
Fig. 8. Fluorescence microscopy images of NIH-3T3. (A) Cells were treated with TGA-QDs/anti-HER2 for 2 h at 37 ◦C, (B) overlap of two images, control nuclei staining with
DAPI.
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Anti-HER2 TGA-QDs nonspeciﬁcally bound to NIH-3T3 cells, but
he ﬂuorescence signals were much lower than those in A549 cells
Fig. 8A and B). The results from ﬂuorescence microscopy were
onsistent with our ﬂow cytometry results.
. Conclusion
Water-soluble TGA-QDs were synthesized and conjugated to
nti-HER2 antibodies. PCR and ﬂow cytometry demonstrated that
549 cells expressed high levels of HER2, whereas NIH-3T3 cells
id not. Antibody-conjugated TGA-QDs bound A549 cells and were
ndocytosed by receptor-mediated endocytosis at 37 ◦C. When
ndocytosis was blocked by incubation at 4 ◦C, QDs bound cells, but
ere not endocytosed. Cellular localization of TGA-QDs and biocon-
ugates were easily determined by nuclear staining, and differences
n localization were clearly observed. Taken together, these results
uggest that TGA-QDs/anti-HER2 can be used as ﬂuorescent probes
or cellular imaging of HER2-overexpressing cancer cells and in vivo
maging applications, such as biomarker detection.
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